Putnam Investments’s Ascendis Pharma A/S ASND Stock Holding History

Putnam Investments’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$91.4M	Sell	725,651 -46,711	-6%	-$4.66M	0.12%	127
2023 Q3	$72.3M	Sell	772,362 -127,470	-14%	-$11.9M	0.11%	128
2023 Q2	$80.3M	Buy	899,832 +158,970	+21%	+$13.8M	0.12%	128
2023 Q1	$79.4M	Buy	740,862 +34,453	+5%	+$3.94M	0.13%	131
2022 Q4	$86.3M	Sell	706,409 -81,656	-10%	-$9.48M	0.15%	122
2022 Q3	$81.4M	Sell	788,065 -15,846	-2%	-$1.5M	0.15%	120
2022 Q2	$74.7M	Buy	803,911 +171,742	+27%	+$16.2M	0.13%	126
2022 Q1	$74.2M	Buy	632,169 +131,054	+26%	+$15.2M	0.11%	138
2021 Q4	$67.4M	Buy	501,115 +47,154	+10%	+$7.01M	0.1%	141
2021 Q3	$72.4M	Buy	453,961 +32,488	+8%	+$4.45M	0.11%	150
2021 Q2	$55.4M	Buy	421,473 +320,657	+318%	+$42.7M	0.09%	163
2021 Q1	$13M	Sell	100,816 -109,863	-52%	-$16.7M	0.02%	330
2020 Q4	$35.1M	Sell	210,679 -179,408	-46%	-$29.7M	0.06%	190
2020 Q3	$60.2M	Sell	390,087 -191,921	-33%	-$27.6M	0.12%	149
2020 Q2	$86.1M	Buy	582,008 +13,137	+2%	+$1.8M	0.18%	112
2020 Q1	$64.1M	Buy	568,871 +394,924	+227%	+$51.3M	0.17%	125
2019 Q4	$24.2M	Buy	173,947 +1,151	+0.7%	+$128K	0.05%	240
2019 Q3	$16.6M	Sell	172,796 -75,920	-31%	-$8.47M	0.04%	282
2019 Q2	$28.6M	Buy	248,716 +80,805	+48%	+$9.67M	0.06%	214
2019 Q1	$19.8M	Buy	167,911 +8,855	+6%	+$775K	0.05%	246
2018 Q4	$9.96M	Sell	159,056 -5,407	-3%	-$340K	0.03%	317
2018 Q3	$11.7M	Buy	+164,463	New	+$11.3M	0.03%	357
2015 Q3	–	Sell	-18,809	Closed	-$331K	–	1471
2015 Q2	$331K	Hold	18,809	–	–	﹤0.01%	1406
2015 Q1	$326K	Buy	+18,809	New	+$342K	﹤0.01%	1390

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Putnam Investments's ASND Position: Q4 2023 in Review

Putnam Investments reduced its Ascendis Pharma A/S (ASND) stake by 6% in Q4 2023, selling an estimated $4.66M and leaving 725,651 shares worth $91.4M. The position accounts for 0.12% of the portfolio, ranked #127.

Putnam Investments first reported a position in ASND in Q1 2015 and has held it in 24 quarters since. 185 funds tracked by Wall St. Rank hold ASND as of Q4 2023.

Putnam Investments held 725,651 shares of Ascendis Pharma A/S worth $91.4M as of Q4 2023.
Putnam Investments sold 46,711 Ascendis Pharma A/S shares in Q4 2023, an estimated $4.66M.
Ascendis Pharma A/S made up 0.12% of Putnam Investments's portfolio in Q4 2023, its #127 holding.
Putnam Investments first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 24 quarters since.
185 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.